The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis

[1]  E. Leray,et al.  Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal , 2022, Neurotherapeutics.

[2]  L. Kremer,et al.  Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study , 2022, Journal of Neurology.

[3]  E. Leray,et al.  Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts , 2021, CNS Drugs.

[4]  D. Arnold,et al.  Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study , 2020, BMJ Open.

[5]  F. Piehl,et al.  Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis , 2019, European journal of neurology.

[6]  Yanli Zhang,et al.  Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis , 2019, Journal of Neurology.

[7]  Howard Thom,et al.  Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. , 2019, Multiple sclerosis and related disorders.

[8]  T. Vollmer,et al.  Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment , 2018, Annals of clinical and translational neurology.

[9]  L. Kappos,et al.  Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis , 2018, Multiple sclerosis.

[10]  F. Piehl,et al.  Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis , 2018, JAMA neurology.

[11]  M. Tsolaki,et al.  Data quality evaluation for observational multiple sclerosis registries , 2017, Multiple sclerosis.

[12]  P. Soelberg Sørensen,et al.  A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod , 2017, Multiple sclerosis.

[13]  A. Traboulsee,et al.  Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis , 2017, The New England journal of medicine.

[14]  H. Butzkueven,et al.  Observational data: Understanding the real MS world , 2016, Multiple sclerosis.

[15]  F. Piehl,et al.  Rituximab versus fingolimod after natalizumab in multiple sclerosis patients , 2016, Annals of neurology.

[16]  V. Martinelli,et al.  Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies , 2016, Multiple sclerosis.

[17]  G. Filippini,et al.  Fingolimod for relapsing-remitting multiple sclerosis. , 2016, The Cochrane database of systematic reviews.

[18]  L. Alfredsson,et al.  Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis , 2016, Multiple sclerosis.

[19]  C. Pozzilli,et al.  Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. , 2015, Brain : a journal of neurology.

[20]  Pierre Grammond,et al.  Defining reliable disability outcomes in multiple sclerosis. , 2015, Brain : a journal of neurology.

[21]  J. Lechner-Scott,et al.  Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis , 2015, Annals of neurology.

[22]  Christian Confavreux,et al.  Randomized trial of oral teriflunomide for relapsing multiple sclerosis. , 2011, The New England journal of medicine.

[23]  G. Comi,et al.  Freedom from disease activity in multiple sclerosis , 2010, Neurology.

[24]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[25]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[26]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[27]  Zhongheng Zhang,et al.  Propensity score method: a non-parametric technique to reduce model dependence. , 2017, Annals of translational medicine.

[28]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .